Apr 14, 2026
Travere Therapeutics (TVTX) Stock Rockets 44% on Groundbreaking FSGS Treatment Approval
Travere Therapeutics (TVTX) stock rallied 44% after FDA approved FILSPARI for FSGS treatment, targeting over 30,000 U.S. patients with this rare disease.
The post Travere Therapeutics (TVTX) Stock Rockets 44% on Groundbreaking FSGS Treatment Approval appeared first on Blockonomi.
Source: Blockonomi →Related News
- 8 hours ago
Apple (AAPL) Stock: Q2 Earnings Beat Expectations with 17% Revenue Jump and $100...
- 11 hours ago
Alphabet (GOOGL) Stock Soars 10% as Q1 Results Demolish Analyst Projections
- 11 hours ago
Amazon (AMZN) Stock Dips After Strong Q1 Earnings — What Spooked Investors?
- 11 hours ago
CoreWeave (CRWV) Stock Climbs 8% Despite $45M Insider Share Dump
- 12 hours ago
Nvidia (NVDA) Tumbles 4% Amid Rising Competition from Google and Amazon Custom C...